LNWTC
AEON icon

Laird Norton Wetherby Trust Company’s AEON Biopharma AEON Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,000
Closed -$16.5K – 983
2025
Q4 		$16.5K Buy
+15,000
New +$14K ﹤0.01% 1020

Other funds holding AEON

DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Laird Norton Wetherby Trust Company's AEON Position: Q1 2026 in Review

Laird Norton Wetherby Trust Company sold out of AEON Biopharma (AEON) in Q1 2026, closing a stake of 15,000 shares — an estimated $16.5K sold.

Laird Norton Wetherby Trust Company first reported a position in AEON in Q4 2025 and held it in 1 quarter. The position peaked at $16.5K in Q4 2025. 24 funds tracked by Wall St. Rank hold AEON as of Q1 2026.

  • Laird Norton Wetherby Trust Company reported no remaining AEON Biopharma position as of Q1 2026 after selling out during the quarter.
  • Laird Norton Wetherby Trust Company sold 15,000 AEON Biopharma shares in Q1 2026, an estimated $16.5K.
  • Laird Norton Wetherby Trust Company first reported a position in AEON Biopharma in Q4 2025 and held it in 1 quarter.
  • Laird Norton Wetherby Trust Company's AEON Biopharma position peaked at $16.5K in Q4 2025.
  • 24 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2026.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q1 2026, filed 15 May 2026.